Flavonoid GL-V9 as a novel and potent acetyl-coa carboxylase 1 inhibitor confers cisplatin hypersensitivity in ovarian cancer
GL-V9 overcomes cisplatin resistance in ovarian cancer by targeting ACC1 and elevating ROS levels, highlighting its potential as a clinically translatable therapeutic strategy.
Authors
- Baosheng Huang
- Hongchuan Zhang
- Jie Zhu (ORCID: https://orcid.org/0000-0002-1879-983X)
- Qinglong Guo
- Guo Chen (ORCID: https://orcid.org/0000-0001-8886-1873)
- Yongjian Guo
- Zihao Jiang
- Yelin Cai
- Zeyuan Lu
- Cong Wang
Institutions
- China Pharmaceutical University (CN)
- First People's Hospital of Chongqing (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Phytomedicine
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1016/j.phymed.2026.158021
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00